


HEALTHCARE

The European Generics Outlook

A country-by-country analysis of developing market opportunities and revenue defense strategies

By Peter Wittner

 [Table of Contents](#)

Peter Wittner

Peter Wittner is an independent consultant in the field of generic pharmaceuticals and the author of a previous report on this topic. He draws on nearly 30 years experience in the pharmaceutical industry in a variety of commercial positions right up to Managing Director.

The last 15 years have been spent specifically in the generic sector in a range of roles including European Sales & Marketing Manager for Norton and MD of Ranbaxy UK at the time of its establishment in the UK.

Copyright © 2003 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Printed and bound in Great Britain by MBA Group Limited, MBA House, Garman Road, London N17 0HW. www.mba-group.com

Table of Contents

The European Generics Outlook

A country-by-country analysis of developing market opportunities and revenue defence strategies

Foreword	12	
Chapter 1	European Market Overview	18
Overview		18
Market sizes by country		20
Generic penetration by country, 2001		22
Generic shares of pharma markets		23
Factors influencing generic share		23
Price levels		23
Intellectual property legislation		24
Pressures on GPs to prescribe generically		24
Legislation permitting generic substitution		24
Regulatory issues – MRP/SmPCs, Bioequivalence and the 10-year rule		24
The Mutual Recognition Procedure		25
Bioequivalence		27
The 10-year/6-year rule		30
Intellectual property, patents and SPCs, Roche-Bolar		33
Patents		33
SPCs		35
What is Roche-Bolar?		35
Low cost versus quality; is it possible to have both?		37
Multinationals who have changed their mind – what went wrong?		38
Factors behind the development of an active generic market – the North-South divide?		40
Market fragmentation – will any truly pan-European players emerge?		44
Chapter 2	The UK	48
Introduction		48
The major factors that are necessary for the development of a healthy generic market		48

High-priced branded products	48
Strong intellectual property legislation	49
High levels of generic prescribing	49
Large number of competing suppliers	50
Market size and major companies	51
Foreign generics companies in the UK	53
Pricing and factors that influence it	54
Government reluctance to fix prices	54
Narrow margins for generics	55
Impact of the Drug Tariff system	55
Parallel imports	58
Impact of patent expiries	58
Patient packs	59
Distribution methods	60
Direct pharmacy sales	61
Wholesalers	61
Short line wholesalers	62
Regulatory environment	62
Intellectual property – patent law	63
The future	63

Chapter 3 Germany 66

Introduction	66
Factors encouraging the development of a healthy generic market	67
The reference pricing system	67
Problems associated with specifying the generic manufacturer when prescribing	67
Rates of generic prescribing	68
Market size and major companies	70
Ratiopharm dominates the market	71
Hexal pursues a different expansion strategy	73
Stada's acquisition-based approach	73
Pricing and factors that influence it	74
Introduction of the <i>Referenzpreis</i> system	75
Step 1	75
Step 2	76
Step 3	77
Measures directed at doctors	78
<i>Aut idem</i>	80
Patient co-payments	81
Patent expiries	82
Impact of parallel imports	83
Regulatory environment	84
Intellectual property	84

Chapter 4 France 87

Introduction	87
Rapid expansion	88
France as a low-priced pharmaceuticals market	89
Measures to encourage the pharmacist	90
Measures to encourage doctors	92
Market size and major companies	93
Pricing	95
Distribution	97
Regulatory issues	98

Chapter 5 The Netherlands 101

Introduction	101
High pharmaceutical prices	101
Strong intellectual property legislation	102
Generic prescribing levels	103
Proposed pharmacy claw back for generics	104
A large number of generic suppliers	105
Pharmacists are free to substitute	105
Market size and major companies	105
Pricing and factors that influence it	106
Pharmacist incentives to substitute	107
Falling generic prices	107
Regulatory environment	109
Intellectual property	109

Chapter 6 Scandinavia 112

Introduction	112
Market size and major companies	114
Denmark	114
Finland	114
Norway	116
Sweden	117
Pricing and factors that influence it	118
Distribution	119

Chapter 7 Spain 122

Introduction	122
Market size and companies	124
Measures to encourage pharmacists	126
Measures to encourage doctors	127
Pricing and factors that influence it	127
Regulatory environment	128
Intellectual property	129

Chapter 8 Italy 132

Introduction	132
Resistors to the development of a generics market	133
Italy as a low-priced market	133
Lack of strong intellectual property legislation	133
The lack of incentives to either physicians or pharmacists	134
Government initiatives to boost generics	134
Problem identification	134
Generic companies start to recognise the potential in Italy	135
Market size and leading companies	135
Recent measures to promote generics	136
The 2003 finance bill	136
A greater role for pharmacists	137
Reimbursement categories	137
More generic registrations	137
A generic substitution law	138
A new reimbursement system	138
Wholesaling and distribution	139

Chapter 9 Other European Markets 142

Introduction	142
Austria	142
Generic market	142
Active companies	142
Regulatory environment	143
Future potential	144
Belgium	144
Generic market	144
Active companies	145
Regulatory environment	146

Future potential	147	
Greece	147	
Generic market	147	
Active companies	148	
Regulatory environment	148	
Future potential	149	
Ireland	149	
Generic market	149	
Active companies	149	
Regulatory environment	150	
Portugal	151	
Generic market	151	
Active companies	151	
Regulatory environment	152	
Future potential	153	
Eastern Europe	153	
Poland	155	
	Regulatory environment	155
	Active companies	155
	Generic market	156
	Future potential	156
Hungary	157	
	Active companies	157
	Regulatory environment	157
	Future potential	158
Czech Republic	158	
	Generic market and active companies	158
	Regulatory environment	158
Other accession countries	159	

Chapter 10 Future Market Trends 162

Targeting southern European markets	162
Deeper generic penetration to counter rising healthcare costs	162
Pressurising the R&D industry	163
Country-by-country analysis	164
Patent expiries	165
Regulatory change	167

Chapter 11 Future Sources of Generics 170

Introduction	170
---------------------	------------

Figure 10.9:	Country-by-country analysis of sources of future generics growth potential	164
Figure 10.10:	Timeline of patent expiries on the world's top selling drugs, 1999–2014	166
Figure 12.11:	New NCEs by year, 1990–2000	181

List of Tables

Table 1.1:	Best selling pharmaceuticals and patent expiry dates, 2001	14
Table 1.2:	European generic market sizes at ex-factory price levels, 1996/97	21
Table 1.3:	Generic penetration by country, 2001	22
Table 1.4:	EC data exclusivity times, early 2003	32
Table 1.5:	Examples of R&D multinationals active in generics in early 2003	39
Table 1.6:	Differing generic penetration rates across Europe	41
Table 1.7:	Comparison of different national pharmaceutical price levels, 2000	42
Table 1.8:	Comparison of different national price levels for a basket of medicines, 2000	43
Table 2.9:	Rates of generic prescribing in the UK, 1987–2001	49
Table 2.10:	Leading generics companies in the UK ranked by turnover	52
Table 2.11:	Non-UK ownership of selected UK generics companies	53
Table 2.12:	Patent expiry dates for selected leading UK products	64
Table 3.13:	Sick fund generic prescribing – Germany	68
Table 3.14:	Turnover and value in units of the leading German generic companies, 2002	72
Table 3.15:	German drug price comparisons, 1991 and 1998	75
Table 3.16:	German DDD cost comparisons, 1991 and 2001	78
Table 4.17:	Evolution of the generic market share in France, 1999–2001	87
Table 4.18:	Comparison of French prices to European average, 2001	89
Table 4.19:	European per-capita drug consumption, 1997 and 2001	96
Table 4.20:	Turnover through distribution channels, 2001	97
Table 5.21:	Evolution of prices in the Netherlands compared to other EU countries, 1996–2000	102
Table 5.22:	Breakdown of prescriptions in the Netherlands, 1994–2001	103
Table 5.23:	Leading generic firms and ownership in the Netherlands	106
Table 5.24:	Comparison of generic prices in the Netherlands, 1995 and 2002	108
Table 6.25:	Breakdown of Scandinavian pharma markets – key data	112
Table 7.26:	Leading generics companies in Spain by revenue, 2002	124
Table 7.27:	Non-Spanish ownership of selected generics companies active in Spain	125
Table 8.28:	Selected leading companies in the Italian generics market and their ownership	136
Table 9.29:	Leading generics companies in Greece by revenue, 2002	148
Table 9.30:	Ownership of selected leading generics companies in Poland, 2003	156
Table 12.31:	Company names that disappeared during the 1990s	179